- Home
- KYMR vs BLTE Comparison
KYMR vs BLTE Comparison
Compare KYMR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- BLTE
- Stock Information
- Founded
- KYMR 2015
- BLTE 2018
- Country
- KYMR United States
- BLTE United States
- Employees
- KYMR N/A
- BLTE N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- KYMR Health Care
- BLTE Health Care
- Exchange
- KYMR Nasdaq
- BLTE Nasdaq
- Market Cap
- KYMR 2.2B
- BLTE 2.1B
- IPO Year
- KYMR 2020
- BLTE 2022
- Fundamental
- Price
- KYMR $29.62
- BLTE $66.70
- Analyst Decision
- KYMR Buy
- BLTE Strong Buy
- Analyst Count
- KYMR 13
- BLTE 4
- Target Price
- KYMR $56.69
- BLTE $96.67
- AVG Volume (30 Days)
- KYMR 591.0K
- BLTE 53.3K
- Earning Date
- KYMR 05-01-2025
- BLTE 03-17-2025
- Dividend Yield
- KYMR N/A
- BLTE N/A
- EPS Growth
- KYMR N/A
- BLTE N/A
- EPS
- KYMR N/A
- BLTE N/A
- Revenue
- KYMR $47,072,000.00
- BLTE N/A
- Revenue This Year
- KYMR $44.93
- BLTE N/A
- Revenue Next Year
- KYMR N/A
- BLTE N/A
- P/E Ratio
- KYMR N/A
- BLTE N/A
- Revenue Growth
- KYMR N/A
- BLTE N/A
- 52 Week Low
- KYMR $29.07
- BLTE $31.01
- 52 Week High
- KYMR $53.27
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- KYMR 33.94
- BLTE 58.99
- Support Level
- KYMR $29.83
- BLTE $64.10
- Resistance Level
- KYMR $35.28
- BLTE $67.40
- Average True Range (ATR)
- KYMR 1.79
- BLTE 2.33
- MACD
- KYMR -0.20
- BLTE -0.33
- Stochastic Oscillator
- KYMR 4.54
- BLTE 37.74
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.